Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 15;73(6):949-956.
doi: 10.1093/cid/ciab121.

Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study

Yuwei Sun  1 , Eric Kim  1 , Christina L Kong  1 , Benjamin F Arnold  1   2 , Travis C Porco  1   2   3 , Nisha R Acharya  1   2   3   4
Affiliations

Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study

Yuwei Sun et al. Clin Infect Dis. .

Abstract

Background: The recombinant zoster vaccine had over 90% efficacy in preventing herpes zoster in clinical trials. However, its effectiveness outside of a clinical trial setting has not been investigated. This study aimed to assess the effectiveness of the recombinant zoster vaccine in general practice.

Methods: A de-identified administrative claims database, the OptumLabs Data Warehouse, was used to conduct this retrospective cohort study to assess the effectiveness of the recombinant zoster vaccine against herpes zoster in nonimmunocompromised, vaccine age-eligible individuals enrolled in the database for ≥365 days.

Results: A total of 4 769 819 adults were included in this study, with 173 745 (3.6%) adults receiving 2 valid doses of the recombinant zoster vaccine. The incidence rate of herpes zoster was 258.8 (95% confidence interval [CI], 230.0-289.4) cases per 100 000 person-years in vaccinated persons compared with 893.1 (95% CI, 886.2-900.0) in unvaccinated persons. Recombinant zoster vaccine effectiveness was 85.5% (95% CI, 83.5-87.3%) overall, with an effectiveness of 86.8% (95% CI, 84.6-88.7%) in individuals 50 to 79 years old compared with 80.3% (95% CI, 75.1-84.3%) in individuals aged 80 and older. In patients with a history of live zoster vaccine within 5 years of study inclusion, vaccine effectiveness was 84.8% (95% CI, 75.3-90.7%).

Conclusions: Recombinant zoster vaccine effectiveness against herpes zoster was high in a real-world setting. Given the low vaccine coverage and high effectiveness, a major public health effort is needed to identify and address barriers to vaccination and increase immunization rates.

Keywords: epidemiology; herpes zoster; infectious disease; real world evidence; recombinant zoster vaccine; shingrix vaccine; vaccine effectiveness.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow diagram of inclusion and exclusion criteria for study cohort. aIndex date was defined as the date at which an individual was eligible for study inclusion. bOf the 116 153 individuals who only had a single valid dose of RZV, 106 462 (91.7%) of them completed 1 dose during the study period, with 9691 (8.3%) of the individuals having an improperly spaced second dose. cTwo valid doses of RZV were defined as receiving the second dose between 30 and 210 days after the first dose. Abbreviations: HZ, herpes zoster; ICD, International Classification of Diseases; OLDW, OptumLabs Data Warehouse; RZV, recombinant zoster vaccine.
Figure 2.
Figure 2.
Recombinant zoster vaccine effectiveness by age, sex, race/ethnicity, and region from 2018 to 2019. aValues are reported as percentages. bVaccine effectiveness was adjusted using inverse probability weighting for age, sex, race, region, prior zoster vaccine live, antiviral use, healthcare utilization, and Charlson comorbidity index. cThe unknown race/ethnicity category includes individuals with either unknown or missing race/ethnicity. Abbreviation: CI, confidence interval.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Thompson RR, Kong CL, Porco TC, Kim E, Ebert CD, Acharya NR. Herpes zoster and postherpetic neuralgia: changing incidence rates from 1994 to 2018 in the United States [manuscript published online ahead of print 23 August 2020]. Clin Infect Dis 2020; doi:10.1093/cid/ciaa1185 - DOI - PMC - PubMed
    1. Harpaz R, Leung JW. The epidemiology of herpes zoster in the United States during the era of varicella and herpes zoster vaccines: changing patterns among older adults. Clin Infect Dis 2019; 69:341–4. - PubMed
    1. Wolfson LJ, Daniels VJ, Altland A, Black W, Huang W, Ou W. The impact of varicella vaccination on the incidence of varicella and herpes zoster in the United States: updated evidence from observational databases, 1991–2016. Clin Infect Dis 2020; 70:995–1002. - PubMed
    1. Kong CL, Thompson RR, Porco TC, Kim E, Acharya NR. Incidence rate of herpes zoster ophthalmicus: a retrospective cohort study from 1994 through 2018. Ophthalmology 2020; 127:324–30. - PMC - PubMed
    1. Cohen JI. Clinical practice: herpes zoster. N Engl J Med 2013; 369:255–63. - PMC - PubMed

Publication types

Substances